HER2陽性子宮内膜漿液性癌または癌肉腫に対する通常の化学療法へのトラスツズマブまたはトラスツズマブ/ペルツズマブの追加の試験
HER2陽性、ステージI~IVの子宮内膜漿液性癌または癌肉腫における、パクリタキセル/カルボプラチン単独、またはトラスツズマブとヒアルロニダーゼ-Oysk(HERCEPTIN HYLECTA)またはペルツズマブ、トラスツズマブ、およびヒアルロニダーゼ-Zzxf(PHESGO)との併用の第II / III相試験
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta [TM]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo [TM]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
調査の概要
状態
詳細な説明
PRIMARY OBJECTIVES:
I. To evaluate the efficacy of trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) and pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO) in combination with paclitaxel/carboplatin in patients with HER2 positive endometrial cancer.
SECONDARY OBJECTIVES:
I. To evaluate the efficacy of trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) and pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO) in combination with paclitaxel/carboplatin in patients with HER2 positive endometrial cancer.
II. To evaluate the overall response rate (ORR) in patients with measurable disease.
III. To evaluate the duration of objective response in patients with measurable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
IV. To determine the nature, frequency and degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 5.0 for each treatment arm.
V. To compare quality of life (QOL), as measured by Functional Assessment of Cancer Therapy - Endometrial Trial Outcome Index (FACT-En-TOI), in the experimental versus control arms.
VI. To compare patient-reported treatment-associated symptoms (diarrhea and rash) as measured with the Patient Reported Outcomes (PRO) - CTCAE, patient-reported fatigue as measured with the Patient Reported Outcomes Measurement Information System (PROMIS)-Fatigue short form, and worry concerning side effects of treatment as measured by the item 'bothered by side effect', in the FACT-En TOI, respectively, in the experimental and control arms.
VII. To assess the correlation of HER2 immunohistochemistry (IHC) expression and in situ hybridization (ISH) amplification with clinical outcome and response to HER2 targeted therapies.
EXPLORATORY OBJECTIVE:
I. To explore time to sustained deterioration in quality of life, as measured by a drop in the FACT-En-TOI by 6 or more points lasting for more than one PRO time point, in the experimental and control arms.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease (SD) or partial response (PR) who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician.
ARM II: Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and trastuzumab/hyaluronidase-oysk subcutaneously (SC) over 2-5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician.
MAINTENANCE: Patients receive trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance therapy for up to 3 years from the start of treatment.
ARM III: Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and pertuzumab/trastuzumab/hyaluronidase-zzxf SC over 5-8 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician.
MAINTENANCE: Patients receive pertuzumab/trastuzumab/ hyaluronidase-zzxf SC over 5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 1 year in absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance for up to 3 years from the start of treatment.
Patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) and computed tomography (CT) throughout the study. Additionally, patients may optionally undergo blood sample collection throughout the study, vaginal brachytherapy on study, and urine sample collection prior to treatment.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35233
- University of Alabama at Birmingham Cancer Center
-
-
Alaska
-
Anchorage、Alaska、アメリカ、99508
- Alaska Women's Cancer Care
-
-
Arizona
-
Tucson、Arizona、アメリカ、85719
- Banner University Medical Center - Tucson
-
Tucson、Arizona、アメリカ、85719
- University of Arizona Cancer Center-North Campus
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ、72205
- University of Arkansas for Medical Sciences
-
-
California
-
Auburn、California、アメリカ、95602
- Sutter Auburn Faith Hospital
-
Berkeley、California、アメリカ、94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Concord、California、アメリカ、94520
- John Muir Medical Center-Concord
-
Duarte、California、アメリカ、91010
- City of Hope Comprehensive Cancer Center
-
Huntington Beach、California、アメリカ、92648
- City of Hope Seacliff
-
Irvine、California、アメリカ、92618
- Kaiser Permanente-Irvine
-
Irvine、California、アメリカ、92618
- City of Hope at Irvine Lennar
-
Irvine、California、アメリカ、92612
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Long Beach、California、アメリカ、90813
- City of Hope at Long Beach Elm
-
Los Angeles、California、アメリカ、90027
- Kaiser Permanente Los Angeles Medical Center
-
Modesto、California、アメリカ、95355
- Memorial Medical Center
-
Mountain View、California、アメリカ、94040
- Palo Alto Medical Foundation-Gynecologic Oncology
-
Orange、California、アメリカ、92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Orange、California、アメリカ、92868
- Saint Joseph Hospital - Orange
-
Palo Alto、California、アメリカ、94304
- Stanford Cancer Institute Palo Alto
-
Panorama City、California、アメリカ、91402
- Kaiser Permanente - Panorama City
-
Riverside、California、アメリカ、92505
- Kaiser Permanente-Riverside
-
Roseville、California、アメリカ、95661
- Sutter Roseville Medical Center
-
Sacramento、California、アメリカ、95816
- Sutter Medical Center Sacramento
-
Sacramento、California、アメリカ、95817
- University of California Davis Comprehensive Cancer Center
-
San Francisco、California、アメリカ、94115
- California Pacific Medical Center-Pacific Campus
-
Santa Cruz、California、アメリカ、95065
- Palo Alto Medical Foundation-Santa Cruz
-
Sunnyvale、California、アメリカ、94086
- Palo Alto Medical Foundation-Sunnyvale
-
Upland、California、アメリカ、91786
- City of Hope Upland
-
Walnut Creek、California、アメリカ、94598
- John Muir Medical Center-Walnut Creek
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- UCHealth University of Colorado Hospital
-
Denver、Colorado、アメリカ、80206
- UCHealth - Cherry Creek
-
Denver、Colorado、アメリカ、80210
- AdventHealth Porter
-
Grand Junction、Colorado、アメリカ、81505
- Grand Valley Oncology
-
Greeley、Colorado、アメリカ、80631
- Banner North Colorado Medical Center
-
Highlands Ranch、Colorado、アメリカ、80129
- UCHealth Highlands Ranch Hospital
-
Loveland、Colorado、アメリカ、80539
- Banner North Colorado Medical Center - Loveland Campus
-
-
Connecticut
-
Danbury、Connecticut、アメリカ、06810
- Danbury Hospital
-
Derby、Connecticut、アメリカ、06418
- Smilow Cancer Hospital-Derby Care Center
-
Fairfield、Connecticut、アメリカ、06824
- Smilow Cancer Hospital Care Center-Fairfield
-
Glastonbury、Connecticut、アメリカ、06033
- Smilow Cancer Hospital Care Center at Glastonbury
-
Greenwich、Connecticut、アメリカ、06830
- Smilow Cancer Hospital Care Center at Greenwich
-
Guilford、Connecticut、アメリカ、06437
- Smilow Cancer Hospital Care Center - Guilford
-
Hartford、Connecticut、アメリカ、06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
New Haven、Connecticut、アメリカ、06520
- Yale University
-
North Haven、Connecticut、アメリカ、06473
- Yale-New Haven Hospital North Haven Medical Center
-
Norwalk、Connecticut、アメリカ、06856
- Norwalk Hospital
-
Stamford、Connecticut、アメリカ、06902
- Smilow Cancer Hospital Care Center at Long Ridge
-
Torrington、Connecticut、アメリカ、06790
- Smilow Cancer Hospital-Torrington Care Center
-
Trumbull、Connecticut、アメリカ、06611
- Smilow Cancer Hospital Care Center-Trumbull
-
Waterbury、Connecticut、アメリカ、06708
- Smilow Cancer Hospital-Waterbury Care Center
-
Waterford、Connecticut、アメリカ、06385
- Smilow Cancer Hospital Care Center - Waterford
-
-
Delaware
-
Newark、Delaware、アメリカ、19713
- Helen F Graham Cancer Center
-
Newark、Delaware、アメリカ、19713
- Medical Oncology Hematology Consultants PA
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20037
- George Washington University Medical Center
-
Washington D.C.、District of Columbia、アメリカ、20016
- Sibley Memorial Hospital
-
-
Florida
-
Fort Lauderdale、Florida、アメリカ、33316
- Broward Health Medical Center
-
Jupiter、Florida、アメリカ、33458
- Jupiter Medical Center
-
N. Venice、Florida、アメリカ、34275
- Sarasota Memorial Hospital-Venice
-
Orlando、Florida、アメリカ、32803
- AdventHealth Orlando
-
Sarasota、Florida、アメリカ、34239
- Sarasota Memorial Hospital
-
Sarasota、Florida、アメリカ、34239
- Florida Cancer Specialists - Sarasota Downtown
-
Sarasota、Florida、アメリカ、34239
- FPG - Surgical Oncology Clinics Gynecologic Oncology Surgery
-
Venice、Florida、アメリカ、34275
- Florida Cancer Specialists - Venice Pinebrook
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30308
- Emory University Hospital Midtown
-
Atlanta、Georgia、アメリカ、30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta、Georgia、アメリカ、30342
- Emory Saint Joseph's Hospital
-
Atlanta、Georgia、アメリカ、30303
- Grady Health System
-
Atlanta、Georgia、アメリカ、30309
- Piedmont Hospital
-
Augusta、Georgia、アメリカ、30912
- Augusta University Medical Center
-
Decatur、Georgia、アメリカ、30033
- Emory Decatur Hospital
-
Savannah、Georgia、アメリカ、31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Hawaii
-
Honolulu、Hawaii、アメリカ、96813
- Queen's Medical Center
-
Honolulu、Hawaii、アメリカ、96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise、Idaho、アメリカ、83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise、Idaho、アメリカ、83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell、Idaho、アメリカ、83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene、Idaho、アメリカ、83814
- Kootenai Health - Coeur d'Alene
-
Fruitland、Idaho、アメリカ、83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian、Idaho、アメリカ、83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa、Idaho、アメリカ、83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa、Idaho、アメリカ、83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls、Idaho、アメリカ、83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint、Idaho、アメリカ、83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls、Idaho、アメリカ、83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Arlington Heights、Illinois、アメリカ、60005
- Northwest Community Hospital
-
Aurora、Illinois、アメリカ、60504
- Rush-Copley Medical Center
-
Centralia、Illinois、アメリカ、62801
- Centralia Oncology Clinic
-
Chicago、Illinois、アメリカ、60611
- Northwestern University
-
Chicago、Illinois、アメリカ、60637
- University of Chicago Comprehensive Cancer Center
-
Chicago、Illinois、アメリカ、60612
- John H Stroger Jr Hospital of Cook County
-
Chicago、Illinois、アメリカ、60612
- Rush MD Anderson Cancer Center
-
Danville、Illinois、アメリカ、61832
- Carle at The Riverfront
-
DeKalb、Illinois、アメリカ、60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur、Illinois、アメリカ、62526
- Decatur Memorial Hospital
-
Decatur、Illinois、アメリカ、62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham、Illinois、アメリカ、62401
- Crossroads Cancer Center
-
Effingham、Illinois、アメリカ、62401
- Carle Physician Group-Effingham
-
Evanston、Illinois、アメリカ、60201
- NorthShore University HealthSystem-Evanston Hospital
-
Geneva、Illinois、アメリカ、60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview、Illinois、アメリカ、60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Glenview、Illinois、アメリカ、60026
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake、Illinois、アメリカ、60030
- Northwestern Medicine Grayslake Outpatient Center
-
Harvey、Illinois、アメリカ、60426
- Ingalls Memorial Hospital
-
Highland Park、Illinois、アメリカ、60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Hinsdale、Illinois、アメリカ、60521
- Sudarshan K Sharma MD Limited-Gynecologic Oncology
-
Lake Forest、Illinois、アメリカ、60045
- Northwestern Medicine Lake Forest Hospital
-
Mattoon、Illinois、アメリカ、61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox、Illinois、アメリカ、60451
- UC Comprehensive Cancer Center at Silver Cross
-
Normal、Illinois、アメリカ、61761
- Carle Cancer Institute Normal
-
O'Fallon、Illinois、アメリカ、62269
- Cancer Care Center of O'Fallon
-
Orland Park、Illinois、アメリカ、60462
- University of Chicago Medicine-Orland Park
-
Orland Park、Illinois、アメリカ、60462
- Northwestern Medicine Orland Park
-
Rockford、Illinois、アメリカ、61114
- UW Health Carbone Cancer Center Rockford
-
Springfield、Illinois、アメリカ、62702
- Southern Illinois University School of Medicine
-
Springfield、Illinois、アメリカ、62702
- Springfield Clinic
-
Springfield、Illinois、アメリカ、62781
- Springfield Memorial Hospital
-
Urbana、Illinois、アメリカ、61801
- Carle Cancer Center
-
Warrenville、Illinois、アメリカ、60555
- Northwestern Medicine Cancer Center Warrenville
-
Yorkville、Illinois、アメリカ、60560
- Rush-Copley Healthcare Center
-
-
Indiana
-
Carmel、Indiana、アメリカ、46032
- IU Health North Hospital
-
Crown Point、Indiana、アメリカ、46307
- UChicago Medicine Northwest Indiana
-
Crown Point、Indiana、アメリカ、46307
- Northwest Cancer Center - Crown Point
-
Dyer、Indiana、アメリカ、46311
- Northwest Oncology LLC
-
Goshen、Indiana、アメリカ、46526
- Goshen Center for Cancer Care
-
Hobart、Indiana、アメリカ、46342
- Northwest Cancer Center - Hobart
-
Hobart、Indiana、アメリカ、46342
- Saint Mary Medical Center
-
Indianapolis、Indiana、アメリカ、46237
- Franciscan Health Indianapolis
-
Indianapolis、Indiana、アメリカ、46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis、Indiana、アメリカ、46260
- Ascension Saint Vincent Indianapolis Hospital
-
Indianapolis、Indiana、アメリカ、46312
- Saint Catherine Hospital
-
Lafayette、Indiana、アメリカ、47905
- Franciscan Saint Elizabeth Health - Lafayette East
-
Mooresville、Indiana、アメリカ、46158
- Franciscan Health Mooresville
-
Munster、Indiana、アメリカ、46321
- The Community Hospital
-
Munster、Indiana、アメリカ、46321
- Women's Diagnostic Center - Munster
-
South Bend、Indiana、アメリカ、46601
- Memorial Hospital of South Bend
-
Valparaiso、Indiana、アメリカ、46383
- Northwest Cancer Center - Valparaiso
-
-
Iowa
-
Ames、Iowa、アメリカ、50010
- Mary Greeley Medical Center
-
Ames、Iowa、アメリカ、50010
- McFarland Clinic - Ames
-
Boone、Iowa、アメリカ、50036
- McFarland Clinic - Boone
-
Council Bluffs、Iowa、アメリカ、51503
- Heartland Oncology and Hematology LLP
-
Council Bluffs、Iowa、アメリカ、51503
- Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ
-
Fort Dodge、Iowa、アメリカ、50501
- McFarland Clinic - Trinity Cancer Center
-
Iowa City、Iowa、アメリカ、52242
- University of Iowa/Holden Comprehensive Cancer Center
-
Jefferson、Iowa、アメリカ、50129
- McFarland Clinic - Jefferson
-
Marshalltown、Iowa、アメリカ、50158
- McFarland Clinic - Marshalltown
-
-
Kansas
-
Shawnee Mission、Kansas、アメリカ、66204
- AdventHealth Shawnee Mission
-
-
Kentucky
-
Edgewood、Kentucky、アメリカ、41017
- Saint Elizabeth Healthcare Edgewood
-
Lexington、Kentucky、アメリカ、40503
- Baptist Health Lexington
-
Louisville、Kentucky、アメリカ、40207
- Baptist Health Louisville
-
-
Louisiana
-
Baton Rouge、Louisiana、アメリカ、70805
- LSU Health Baton Rouge-North Clinic
-
Baton Rouge、Louisiana、アメリカ、70817
- Our Lady of the Lake Medical Oncology
-
Baton Rouge、Louisiana、アメリカ、70808
- Our Lady of the Lake Physician Group
-
Covington、Louisiana、アメリカ、70433
- Ochsner Hematology Oncology North Shore - Covington (West Region)
-
Marrero、Louisiana、アメリカ、70072
- West Jefferson Medical Center
-
Metairie、Louisiana、アメリカ、70006
- East Jefferson General Hospital
-
Metairie、Louisiana、アメリカ、70006
- LSU Healthcare Network / Metairie Multi-Specialty Clinic
-
New Orleans、Louisiana、アメリカ、70121
- Ochsner Medical Center Jefferson
-
New Orleans、Louisiana、アメリカ、70112
- University Medical Center New Orleans
-
New Orleans、Louisiana、アメリカ、70115
- Ochsner Baptist Medical Center
-
-
Maine
-
Augusta、Maine、アメリカ、04330
- Harold Alfond Center for Cancer Care
-
Scarborough、Maine、アメリカ、04074
- MaineHealth Maine Medical Center- Scarborough
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21237
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute
-
Baltimore、Maryland、アメリカ、21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore、Maryland、アメリカ、21215
- Sinai Hospital of Baltimore
-
Baltimore、Maryland、アメリカ、21204
- Greater Baltimore Medical Center
-
Bethesda、Maryland、アメリカ、20889-5600
- Walter Reed National Military Medical Center
-
Westminster、Maryland、アメリカ、21157
- William E Kahlert Regional Cancer Center/Sinai Hospital
-
-
Massachusetts
-
Springfield、Massachusetts、アメリカ、01199
- Baystate Medical Center
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- University of Michigan Rogel Cancer Center
-
Battle Creek、Michigan、アメリカ、49017
- Bronson Battle Creek
-
Brighton、Michigan、アメリカ、48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Canton、Michigan、アメリカ、48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Chelsea、Michigan、アメリカ、48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Detroit、Michigan、アメリカ、48201
- Wayne State University/Karmanos Cancer Institute
-
Farmington Hills、Michigan、アメリカ、48334
- Weisberg Cancer Treatment Center
-
Farmington Hills、Michigan、アメリカ、48336
- Corewell Health Farmington Hills Hospital
-
Flint、Michigan、アメリカ、48503
- Hurley Medical Center
-
Flint、Michigan、アメリカ、48503
- Genesee Hematology Oncology PC
-
Flint、Michigan、アメリカ、48503
- Genesys Hurley Cancer Institute
-
Flint、Michigan、アメリカ、48503
- Cancer Hematology Centers - Flint
-
Grand Rapids、Michigan、アメリカ、49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids、Michigan、アメリカ、49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo、Michigan、アメリカ、49007
- West Michigan Cancer Center
-
Kalamazoo、Michigan、アメリカ、49007
- Bronson Methodist Hospital
-
Kalamazoo、Michigan、アメリカ、49009
- Beacon Kalamazoo Cancer Center
-
Lansing、Michigan、アメリカ、48912
- University of Michigan Health - Sparrow Lansing
-
Livonia、Michigan、アメリカ、48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Muskegon、Michigan、アメリカ、49444
- Trinity Health Muskegon Hospital
-
Niles、Michigan、アメリカ、49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores、Michigan、アメリカ、49444
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Pontiac、Michigan、アメリカ、48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Reed City、Michigan、アメリカ、49677
- Corewell Health Reed City Hospital
-
Royal Oak、Michigan、アメリカ、48073
- Corewell Health William Beaumont University Hospital
-
Saginaw、Michigan、アメリカ、48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw、Michigan、アメリカ、48601
- MyMichigan Medical Center Saginaw
-
Saint Joseph、Michigan、アメリカ、49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph、Michigan、アメリカ、49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Tawas City、Michigan、アメリカ、48764
- MyMichigan Medical Center Tawas
-
Traverse City、Michigan、アメリカ、49684
- Munson Medical Center
-
Troy、Michigan、アメリカ、48085
- Corewell Health Beaumont Troy Hospital
-
West Branch、Michigan、アメリカ、48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Wyoming、Michigan、アメリカ、49519
- University of Michigan Health - West
-
Ypsilanti、Michigan、アメリカ、48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Coon Rapids、Minnesota、アメリカ、55433
- Mercy Hospital
-
Edina、Minnesota、アメリカ、55435
- Fairview Southdale Hospital
-
Edina、Minnesota、アメリカ、55435
- Minnesota Oncology - Edina
-
Maplewood、Minnesota、アメリカ、55109
- Minnesota Oncology Hematology PA-Maplewood
-
Marshall、Minnesota、アメリカ、56258
- Avera Cancer Institute at Marshall
-
Minneapolis、Minnesota、アメリカ、55407
- Abbott-Northwestern Hospital
-
Minneapolis、Minnesota、アメリカ、55455
- University of Minnesota/Masonic Cancer Center
-
Saint Louis Park、Minnesota、アメリカ、55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul、Minnesota、アメリカ、55101
- Regions Hospital
-
Saint Paul、Minnesota、アメリカ、55102
- United Hospital
-
Woodbury、Minnesota、アメリカ、55125
- Minnesota Oncology Hematology PA-Woodbury
-
-
Missouri
-
Columbia、Missouri、アメリカ、65212
- MU Health - University Hospital/Ellis Fischel Cancer Center
-
Rolla、Missouri、アメリカ、65401
- Phelps Health Delbert Day Cancer Institute
-
Springfield、Missouri、アメリカ、65807
- CoxHealth South Hospital
-
St Louis、Missouri、アメリカ、63110
- Washington University School of Medicine
-
St Louis、Missouri、アメリカ、63141
- Mercy Hospital Saint Louis
-
St Louis、Missouri、アメリカ、63128
- Mercy Hospital South
-
-
Montana
-
Anaconda、Montana、アメリカ、59711
- Community Hospital of Anaconda
-
Billings、Montana、アメリカ、59101
- Billings Clinic Cancer Center
-
Billings、Montana、アメリカ、59102
- Saint Vincent Frontier Cancer Center
-
Billings、Montana、アメリカ、59106
- Intermountain Health West End Clinic
-
Bozeman、Montana、アメリカ、59715
- Bozeman Health Deaconess Hospital
-
Great Falls、Montana、アメリカ、59405
- Benefis Sletten Cancer Institute
-
Kalispell、Montana、アメリカ、59901
- Logan Health Medical Center
-
Missoula、Montana、アメリカ、59802
- Saint Patrick Hospital - Community Hospital
-
Missoula、Montana、アメリカ、59804
- Community Medical Center
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68114
- Nebraska Methodist Hospital
-
Omaha、Nebraska、アメリカ、68198
- University of Nebraska Medical Center
-
Omaha、Nebraska、アメリカ、68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha、Nebraska、アメリカ、68114
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89102
- OptumCare Cancer Care at Charleston
-
Las Vegas、Nevada、アメリカ、89106
- Women's Cancer Center of Nevada
-
Las Vegas、Nevada、アメリカ、89183
- OptumCare Cancer Care at Fort Apache
-
-
New Jersey
-
Basking Ridge、New Jersey、アメリカ、07920
- Memorial Sloan Kettering Basking Ridge
-
Camden、New Jersey、アメリカ、08103
- Cooper Hospital University Medical Center
-
Hackensack、New Jersey、アメリカ、07601
- Hackensack University Medical Center
-
Lakewood、New Jersey、アメリカ、08701
- Monmouth Medical Center Southern Campus
-
Livingston、New Jersey、アメリカ、07039
- Cooperman Barnabas Medical Center
-
Long Branch、New Jersey、アメリカ、07740
- Monmouth Medical Center
-
Middletown、New Jersey、アメリカ、07748
- Memorial Sloan Kettering Monmouth
-
Montvale、New Jersey、アメリカ、07645
- Memorial Sloan Kettering Bergen
-
Moorestown、New Jersey、アメリカ、08057
- Virtua Samson Cancer Center
-
Neptune City、New Jersey、アメリカ、07753
- Jersey Shore Medical Center
-
New Brunswick、New Jersey、アメリカ、08903
- Rutgers Cancer Institute of New Jersey
-
Newark、New Jersey、アメリカ、07101
- Rutgers New Jersey Medical School
-
Red Bank、New Jersey、アメリカ、07701
- Riverview Medical Center/Booker Cancer Center
-
Sewell、New Jersey、アメリカ、08080
- Sidney Kimmel Cancer Center Washington Township
-
Somerville、New Jersey、アメリカ、08876
- Robert Wood Johnson University Hospital Somerset
-
Toms River、New Jersey、アメリカ、08755
- Community Medical Center
-
Voorhees Township、New Jersey、アメリカ、08043
- Virtua Voorhees
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87106
- University of New Mexico Cancer Center
-
Albuquerque、New Mexico、アメリカ、87110
- Presbyterian Kaseman Hospital
-
Rio Rancho、New Mexico、アメリカ、87124
- Presbyterian Rust Medical Center/Jorgensen Cancer Center
-
-
New York
-
Albany、New York、アメリカ、12208
- Women's Cancer Care Associates LLC
-
Commack、New York、アメリカ、11725
- Memorial Sloan Kettering Commack
-
Harrison、New York、アメリカ、10604
- Memorial Sloan Kettering Westchester
-
Mineola、New York、アメリカ、11501
- NYU Langone Hospital - Long Island
-
New York、New York、アメリカ、10065
- Memorial Sloan Kettering Cancer Center
-
New York、New York、アメリカ、10029
- Mount Sinai Hospital
-
New York、New York、アメリカ、10011
- Mount Sinai Chelsea
-
New York、New York、アメリカ、10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester、New York、アメリカ、14642
- University of Rochester
-
Syracuse、New York、アメリカ、13210
- State University of New York Upstate Medical University
-
The Bronx、New York、アメリカ、10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx、New York、アメリカ、10467
- Montefiore Medical Center - Moses Campus
-
The Bronx、New York、アメリカ、10461
- Montefiore Medical Center-Weiler Hospital
-
Uniondale、New York、アメリカ、11553
- Memorial Sloan Kettering Nassau
-
Webster、New York、アメリカ、14580
- Wilmot Cancer Institute at Webster
-
-
North Carolina
-
Cary、North Carolina、アメリカ、27518
- Duke Cancer Center Cary
-
Chapel Hill、North Carolina、アメリカ、27599
- UNC Lineberger Comprehensive Cancer Center
-
Durham、North Carolina、アメリカ、27710
- Duke University Medical Center
-
Greenville、North Carolina、アメリカ、27834
- ECU Health Medical Center
-
High Point、North Carolina、アメリカ、27262
- Hayworth Cancer Center
-
Raleigh、North Carolina、アメリカ、27607
- Duke Women's Cancer Care Raleigh
-
Wilmington、North Carolina、アメリカ、28401
- Novant Health New Hanover Regional Medical Center
-
Winston-Salem、North Carolina、アメリカ、27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Bismarck、North Dakota、アメリカ、58501
- Sanford Bismarck Medical Center
-
Fargo、North Dakota、アメリカ、58122
- Sanford Roger Maris Cancer Center
-
Fargo、North Dakota、アメリカ、58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Beachwood、Ohio、アメリカ、44122
- UHHS-Chagrin Highlands Medical Center
-
Belpre、Ohio、アメリカ、45714
- Strecker Cancer Center-Belpre
-
Canton、Ohio、アメリカ、44710
- Aultman Health Foundation
-
Centerville、Ohio、アメリカ、45459
- Miami Valley Hospital South
-
Chardon、Ohio、アメリカ、44024
- Geauga Hospital
-
Chillicothe、Ohio、アメリカ、45601
- Adena Regional Medical Center
-
Cincinnati、Ohio、アメリカ、45220
- Good Samaritan Hospital - Cincinnati
-
Cleveland、Ohio、アメリカ、44106
- Case Western Reserve University
-
Cleveland、Ohio、アメリカ、44109
- MetroHealth Medical Center
-
Columbus、Ohio、アメリカ、43214
- Riverside Methodist Hospital
-
Columbus、Ohio、アメリカ、43210
- Ohio State University Comprehensive Cancer Center
-
Columbus、Ohio、アメリカ、43219
- The Mark H Zangmeister Center
-
Columbus、Ohio、アメリカ、43213
- Mount Carmel East Hospital
-
Dayton、Ohio、アメリカ、45409
- Miami Valley Hospital
-
Dayton、Ohio、アメリカ、45415
- Miami Valley Hospital North
-
Franklin、Ohio、アメリカ、45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Greenville、Ohio、アメリカ、45331
- Miami Valley Cancer Care and Infusion
-
Grove City、Ohio、アメリカ、43123
- Mount Carmel Grove City Hospital
-
Lancaster、Ohio、アメリカ、43130
- Fairfield Medical Center
-
Lima、Ohio、アメリカ、45801
- Saint Rita's Medical Center
-
Marietta、Ohio、アメリカ、45750
- Marietta Memorial Hospital
-
Marysville、Ohio、アメリカ、43040
- Memorial Hospital
-
Mentor、Ohio、アメリカ、44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Mount Vernon、Ohio、アメリカ、43050
- Knox Community Hospital
-
Newark、Ohio、アメリカ、43055
- Licking Memorial Hospital
-
Parma、Ohio、アメリカ、44129
- University Hospitals Parma Medical Center
-
Perrysburg、Ohio、アメリカ、43551
- Mercy Health - Perrysburg Hospital
-
Portsmouth、Ohio、アメリカ、45662
- Southern Ohio Medical Center
-
Springfield、Ohio、アメリカ、45504
- Springfield Regional Cancer Center
-
Springfield、Ohio、アメリカ、45504
- Springfield Regional Medical Center
-
Sylvania、Ohio、アメリカ、43560
- ProMedica Flower Hospital
-
Toledo、Ohio、アメリカ、43623
- Mercy Health - Saint Anne Hospital
-
Toledo、Ohio、アメリカ、43608
- Mercy Health - Saint Vincent Hospital
-
Troy、Ohio、アメリカ、45373
- Upper Valley Medical Center
-
Westerville、Ohio、アメリカ、43081
- Saint Ann's Hospital
-
Westlake、Ohio、アメリカ、44145
- UH Seidman Cancer Center at Saint John Medical Center
-
Zanesville、Ohio、アメリカ、43701
- Genesis Healthcare System Cancer Care Center
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City、Oklahoma、アメリカ、73120
- Mercy Hospital Oklahoma City
-
Tulsa、Oklahoma、アメリカ、74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Clackamas、Oregon、アメリカ、97015
- Providence Cancer Institute Clackamas Clinic
-
Newberg、Oregon、アメリカ、97132
- Providence Newberg Medical Center
-
Ontario、Oregon、アメリカ、97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland、Oregon、アメリカ、97239
- Oregon Health and Science University
-
Portland、Oregon、アメリカ、97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland、Oregon、アメリカ、97213
- Providence Portland Medical Center
-
Portland、Oregon、アメリカ、97225
- Providence Saint Vincent Medical Center
-
Tualatin、Oregon、アメリカ、97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Allentown、Pennsylvania、アメリカ、18103
- Lehigh Valley Hospital-Cedar Crest
-
Allentown、Pennsylvania、アメリカ、18104
- Saint Luke's Cancer Center - Allentown
-
Bethlehem、Pennsylvania、アメリカ、18017
- Lehigh Valley Hospital - Muhlenberg
-
Bethlehem、Pennsylvania、アメリカ、18015
- Saint Luke's University Hospital-Bethlehem Campus
-
Bryn Mawr、Pennsylvania、アメリカ、19010
- Bryn Mawr Hospital
-
East Stroudsburg、Pennsylvania、アメリカ、18301
- Pocono Medical Center
-
Easton、Pennsylvania、アメリカ、18045
- Saint Luke's Hospital-Anderson Campus
-
Erie、Pennsylvania、アメリカ、16544
- Saint Vincent Hospital
-
Hazleton、Pennsylvania、アメリカ、18201
- Lehigh Valley Hospital-Hazleton
-
Jefferson Hills、Pennsylvania、アメリカ、15025
- Jefferson Hospital
-
Media、Pennsylvania、アメリカ、19063
- Riddle Memorial Hospital
-
Monroeville、Pennsylvania、アメリカ、15146
- Forbes Hospital
-
Paoli、Pennsylvania、アメリカ、19301
- Paoli Memorial Hospital
-
Philadelphia、Pennsylvania、アメリカ、19111
- Fox Chase Cancer Center
-
Philadelphia、Pennsylvania、アメリカ、19107
- Thomas Jefferson University Hospital
-
Philadelphia、Pennsylvania、アメリカ、19107
- Pennsylvania Hospital
-
Pittsburgh、Pennsylvania、アメリカ、15224
- West Penn Hospital
-
Quakertown、Pennsylvania、アメリカ、18951
- Saint Luke's Hospital - Upper Bucks Campus
-
West Chester、Pennsylvania、アメリカ、19380
- Chester County Hospital
-
Wexford、Pennsylvania、アメリカ、15090
- Wexford Health and Wellness Pavilion
-
Willow Grove、Pennsylvania、アメリカ、19090
- Asplundh Cancer Pavilion
-
Wynnewood、Pennsylvania、アメリカ、19096
- Lankenau Medical Center
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02905
- Women and Infants Hospital
-
Westerly、Rhode Island、アメリカ、02891
- Smilow Cancer Hospital Care Center - Westerly
-
-
South Carolina
-
Bluffton、South Carolina、アメリカ、29910
- Saint Joseph's/Candler - Bluffton Campus
-
Charleston、South Carolina、アメリカ、29425
- Medical University of South Carolina
-
-
South Dakota
-
Aberdeen、South Dakota、アメリカ、57401
- Avera Cancer Institute-Aberdeen
-
Rapid City、South Dakota、アメリカ、57701
- Rapid City Regional Hospital
-
Sioux Falls、South Dakota、アメリカ、57105
- Avera Cancer Institute
-
Sioux Falls、South Dakota、アメリカ、57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls、South Dakota、アメリカ、57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Germantown、Tennessee、アメリカ、38138
- The West Clinic - Wolf River
-
-
Texas
-
Austin、Texas、アメリカ、78712
- University of Texas at Austin
-
Austin、Texas、アメリカ、78701
- Dell Seton Medical Center at The University of Texas
-
Dallas、Texas、アメリカ、75235
- Parkland Memorial Hospital
-
Dallas、Texas、アメリカ、75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Fort Worth、Texas、アメリカ、76104
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Fort Worth、Texas、アメリカ、76104
- Tarrant County Hospital District/JPS Health Network
-
Houston、Texas、アメリカ、77030
- Houston Methodist Hospital
-
Houston、Texas、アメリカ、77030
- Memorial Hermann Texas Medical Center
-
Houston、Texas、アメリカ、77070
- Methodist Willowbrook Hospital
-
Houston、Texas、アメリカ、77094
- Houston Methodist West Hospital
-
Nassau Bay、Texas、アメリカ、77058
- Houston Methodist Saint John Hospital
-
Richardson、Texas、アメリカ、75080
- UT Southwestern Clinical Center at Richardson/Plano
-
Sugar Land、Texas、アメリカ、77479
- Houston Methodist Sugar Land Hospital
-
The Woodlands、Texas、アメリカ、77385
- Houston Methodist The Woodlands Hospital
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- Huntsman Cancer Institute/University of Utah
-
South Jordan、Utah、アメリカ、84009
- South Jordan Health Center
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22908
- University of Virginia Cancer Center
-
Richmond、Virginia、アメリカ、23235
- VCU Massey Cancer Center at Stony Point
-
Richmond、Virginia、アメリカ、23229
- Henrico Doctor's Hospital
-
Richmond、Virginia、アメリカ、23298
- VCU Massey Comprehensive Cancer Center
-
Roanoke、Virginia、アメリカ、24033
- Carilion Roanoke Memorial Hospital
-
-
Washington
-
Edmonds、Washington、アメリカ、98026
- Swedish Cancer Institute-Edmonds
-
Seattle、Washington、アメリカ、98122
- Swedish Medical Center-First Hill
-
Vancouver、Washington、アメリカ、98686
- Legacy Salmon Creek Hospital
-
-
West Virginia
-
Charleston、West Virginia、アメリカ、25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
Morgantown、West Virginia、アメリカ、26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Eau Claire、Wisconsin、アメリカ、54701
- Marshfield Medical Center-EC Cancer Center
-
Green Bay、Wisconsin、アメリカ、54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Green Bay、Wisconsin、アメリカ、54303
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
La Crosse、Wisconsin、アメリカ、54601
- Gundersen Lutheran Medical Center
-
Madison、Wisconsin、アメリカ、53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison、Wisconsin、アメリカ、53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marshfield、Wisconsin、アメリカ、54449
- Marshfield Medical Center-Marshfield
-
Milwaukee、Wisconsin、アメリカ、53226
- Medical College of Wisconsin
-
Minocqua、Wisconsin、アメリカ、54548
- Marshfield Medical Center - Minocqua
-
Mukwonago、Wisconsin、アメリカ、53149
- ProHealth D N Greenwald Center
-
New Richmond、Wisconsin、アメリカ、54017
- Cancer Center of Western Wisconsin
-
Oconomowoc、Wisconsin、アメリカ、53066
- ProHealth Oconomowoc Memorial Hospital
-
Oconto Falls、Wisconsin、アメリカ、54154
- Saint Vincent Hospital Cancer Center at Oconto Falls
-
Rice Lake、Wisconsin、アメリカ、54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan、Wisconsin、アメリカ、53081
- Saint Vincent Hospital Cancer Center at Sheboygan
-
Sheboygan、Wisconsin、アメリカ、53081
- Sheboygan Physicians Group
-
Stevens Point、Wisconsin、アメリカ、54482
- Marshfield Medical Center-River Region at Stevens Point
-
Sturgeon Bay、Wisconsin、アメリカ、54235-1495
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
Waukesha、Wisconsin、アメリカ、53188
- UW Cancer Center at ProHealth Care
-
Weston、Wisconsin、アメリカ、54476
- Marshfield Medical Center - Weston
-
-
-
-
-
San Juan、プエルトリコ、00927
- Centro Comprensivo de Cancer de UPR
-
-
-
-
-
Seoul、韓国、06273
- Gangnam Severance Hospital
-
-
Daegu
-
Dalseo-gu、Daegu、韓国、42601
- Keimyung University-Dongsan Medical Center
-
-
Gyeongsangnam-do
-
Seoul、Gyeongsangnam-do、韓国、51353
- Samsung Changwon Hospital
-
-
Kyeonggi-do
-
Seongnam、Kyeonggi-do、韓国、463-707
- Seoul National University Bundang Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Federation of Gynecology and Obstetrics (FIGO) 2009 stage IA-IVB, non-recurrent, chemotherapy (chemo)-naive, HER2-positive endometrial cancer. The following endometrial cancer types are eligible:
-
Serous
-
Other endometrial cancers (including clear cell, endometrioid, mixed epithelial, dedifferentiated/undifferentiated)
-
Carcinosarcoma
- NOTE: Endometrial cancers that are mismatch repair deficient (dMMR) by IHC are not eligible
-
-
Histologic confirmation of the original primary tumor is required. Submission of surgical pathology report (or endometrial biopsy pathology report in patients who never undergo hysterectomy) is required
-
Patients must be within 8 weeks of primary surgery (or endometrial biopsy in patients who never undergo hysterectomy) at the time of study registration
-
Patients may have measurable disease, non-measurable disease, or no measurable disease. In patients with measurable disease, lesions will be defined and monitored by RECIST v 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be >= 10 mm when measured by CT or magnetic resonance imaging (MRI). Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
-
For patients with uterine-confined (stage I) disease, the tumor must be invasive into the myometrium. Any amount of myoinvasion is acceptable for eligibility. Patients with non-invasive disease, endometrial intraepithelial carcinoma alone, or disease confined to a polyp will be excluded
-
All patients must have tumors that are HER2 positive as defined by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2018 Breast Cancer guidelines. IHC and ISH testing will be done locally, at each participating institution and interpreted by local pathologists. In general HER2 positivity is defined as any of the following:
- 3+ immunohistochemistry (IHC),
- 2+ IHC with positive in situ hybridization (ISH) Alternatively, patients could be eligible if next generation sequencing (NGS) demonstrates HER2 (ERBB2) amplification. NGS testing can be performed through any designated labs as per the National Cancer Institute (NCI) MATCH/NCI Combo-MATCH trial.
Pathology report showing results of institutional HER2 testing (or NGS testing results) must be submitted.
Sites must submit all results available (IHC, ISH, and NGS)
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
-
Age >= 18
-
Platelets >= 100,000/mcl (within 14 days prior to registration)
-
Absolute neutrophil count (ANC) >= 1,500/mcl (within 14 days prior to registration)
-
Creatinine =< 1.5 x institutional/laboratory upper limit of normal (ULN) or estimated Glomerular filtration rate (eGFR) >= 50 mL/min using either the Cockcroft-Gault equation, the Modification of Diet in Renal Disease Study, or as reported in the comprehensive metabolic panel/basic metabolic panel (eGFR) (within 14 days prior to registration)
-
Total serum bilirubin level =< 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =< 3 x ULN may be enrolled) (within 14 days prior to registration)
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (within 14 days prior to registration)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial
-
Although the uterus will have been removed in the vast majority of patients, for patients of child-bearing potential: negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required. Patients will be considered of non-reproductive potential if they are either:
- Postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women < 45 years of age, a high follicle stimulating hormone [FSH] level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient); OR
- Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion at least 6 weeks prior to registration
- Have a congenital or acquired condition that prevents childbearing
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients with evidence of chronic hepatitis B virus (HBV) infection must have an undetectable HBV viral load on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
Exclusion Criteria:
-
Prior Therapy:
-
Patients must NOT have received prior chemotherapy, biologic therapy, or targeted therapy for treatment of endometrial carcinoma
-
Patients must NOT have received prior radiation therapy for treatment of endometrial carcinoma. Prior radiation includes external beam pelvic radiation therapy, external beam extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy
- NOTE: Vaginal brachytherapy for treatment of endometrial cancer is permitted during study treatment. Planned use of vaginal brachytherapy must be declared at time of registration
-
Patients may have received prior hormonal therapy for treatment of endometrial carcinoma. All hormonal therapy must be discontinued at least one week prior to registration
-
-
Patients may not have a planned interval cytoreduction or hysterectomy, prior to documentation of progression, after study registration
-
Patients may not have planned external beam radiotherapy, prior to documentation of progression, after study registration
-
Significant cardiovascular disease including:
- Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm Hg despite antihypertensive medications
- Myocardial infarction or unstable angina within 6 months prior to registration
- New York Heart Association functional classification II, III or IV
- Serious cardiac arrhythmia requiring medication. This does not include asymptomatic, atrial fibrillation with controlled ventricular rate
-
Significant lung disease: dyspnea at rest grade 2 or greater (resulting from extensive tumor involvement or other causes), pneumonitis grade 2 or greater, interstitial lung disease grade 2 or greater, idiopathic pulmonary fibrosis, cystic fibrosis, Aspergillosis, active tuberculosis, or history of opportunistic infections (pneumocystis pneumonia or cytomegalovirus pneumonia)
-
Patients with uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), uncontrolled interstitial lung disease, symptomatic congestive heart failure, or psychiatric illness/social situations that would limit compliance with study requirements
-
Treatment with strong CYP2C8 or CYP3A4 inhibitors or inducers within 14 days or 5 drug-elimination half-lives, whichever is longer, prior to registration
-
Women who are unwilling to discontinue nursing
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Arm I (paclitaxel, carboplatin)
Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician. Patients undergo ECHO or MUGA and CT throughout the study. Additionally, patients may optionally undergo blood sample collection throughout the study, vaginal brachytherapy on study, and urine sample collection prior to treatment. |
Given IV
他の名前:
Given IV
他の名前:
Undergo CT
他の名前:
Undergo ECHO
他の名前:
Undergo MUGA
他の名前:
Undergo blood and urine sample collection
他の名前:
Undergo vaginal brachytherapy
他の名前:
|
|
実験的:Arm II (paclitaxel, carboplatin, Herceptin Hylecta)
Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician. MAINTENANCE: Patients receive trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance therapy for up to 3 years from the start of treatment. Patients undergo ECHO or MUGA and CT throughout the study. Additionally patients may optionally undergo blood sample collection throughout the study, vaginal brachytherapy on study, and urine sample collection prior to treatment. |
Given IV
他の名前:
Given IV
他の名前:
Undergo CT
他の名前:
Undergo ECHO
他の名前:
Undergo MUGA
他の名前:
Undergo blood and urine sample collection
他の名前:
Undergo vaginal brachytherapy
他の名前:
Ancillary studies Given SC
他の名前:
|
|
実験的:Arm III (paclitaxel, carboplatin, Phesgo)
See Detailed Description. |
Given IV
他の名前:
Given IV
他の名前:
Undergo CT
他の名前:
Undergo ECHO
他の名前:
Undergo MUGA
他の名前:
Undergo blood and urine sample collection
他の名前:
Undergo vaginal brachytherapy
他の名前:
Ancillary studies Given SC
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression free survival
時間枠:From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years from randomization
|
At the end of Phase 2 analysis, if both experimental arms demonstrate superiority to the reference, the experimental arms will be compared to each other. |
From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years from randomization
|
|
Overall survival
時間枠:From study entry to time of death or the date of last contact, assessed up to 5 years from randomization
|
If both experimental arms demonstrate superiority to the reference arm, the experimental arms will be compared to each other. |
From study entry to time of death or the date of last contact, assessed up to 5 years from randomization
|
|
Incidence of dose limiting toxicities
時間枠:Up to end of cycle 3 (week 12)
|
A dose limiting toxicity is any treatment-related adverse event requiring permanent discontinuation of the experimental therapy prior to the completion of treatment cycle 3. |
Up to end of cycle 3 (week 12)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective response rate (ORR)
時間枠:Within 12 months of initiating maintenance therapy
|
Defined as the binomial proportion of evaluable patients with a best overall response of complete response or partial response (by Response Evaluation Criteria in Solid Tumors 1.1) within 12 months of initiating maintenance therapy. Responses reported by the treating physician will be used for these analyses. The ORR estimates by treatment arm will be supported by their 2-sided, 95% Wilson-Score confidence intervals (Wilson, 1927; Agresti, 1998). The relative odds of response in each experimental group (versus [vs] the reference group) will be estimated using a multivariable logistic regression model specified with main effects for the treatment groups and covariate adjustments for the stratification factors reported at baseline. |
Within 12 months of initiating maintenance therapy
|
|
Duration of objective response
時間枠:From documentation of either partial response or complete response until disease progression or death, whichever is observed first, assessed up to 5 years from randomization
|
Treatment group differences in response duration will be graphed using Kaplan-Meier methods and compared using logrank tests, stratified by the minimization factors defined at randomization. The relative hazards of progression or death in each experimental group (vs the reference group) will be estimated using a multivariable proportional hazards regression model specified with main effects for the treatment indicators and covariate adjustments for the stratification factors reported at baseline. |
From documentation of either partial response or complete response until disease progression or death, whichever is observed first, assessed up to 5 years from randomization
|
|
Incidence of adverse events (AEs)
時間枠:Up to 5 years from randomization
|
The nature, frequency, and degree of toxicity will be tabulated at the System Organ Class and AE-specific term levels using Common Terminology Criteria version 5.0. Each patient will be represented according to the maximum grade observed for each term. Tabulations will show the number and percentage of patients by maximum grade, within the treatment group received, regardless of the randomized treatment assignment. |
Up to 5 years from randomization
|
|
HER2 expression
時間枠:Up to 5 years from randomization
|
Correlation of HER2 immunohistochemistry expression and in situ hybridization amplification with clinical outcome and response to HER2 targeted therapies will be explored. |
Up to 5 years from randomization
|
|
Quality of life (QoL)
時間枠:Up to 5 years from randomization
|
Measured by Functional Assessment of Cancer Therapy - Endometrial Trial Outcome Index (FACT-En TOI). |
Up to 5 years from randomization
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
QoL deterioration
時間枠:Baseline up to 5 years
|
The deterioration in QoL will be measured by a drop of >= 6 points in the FACT-En TOI score from baseline and lasting for more than one patient reported outcome time point in experimental and control arms. |
Baseline up to 5 years
|
協力者と研究者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 泌尿生殖器疾患
- 生殖器疾患
- 泌尿生殖器腫瘍
- 部位別新生物
- 女性の泌尿生殖器疾患
- 女性の泌尿生殖器疾患と妊娠合併症
- 子宮の病気
- 生殖器疾患、女性
- 性器腫瘍、女性
- 子宮腫瘍
- 新生物
- 子宮内膜腫瘍
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 有機化学物質
- 調査手法
- 臨床検査技術
- 診断技術と手順
- 診断
- 炭化水素
- シクロパラフィン
- 炭化水素、環状
- 炭化水素、周期的
- テルペン
- グリコシドヒドロラーゼ
- ヒドロラーゼ
- 酵素
- 酵素と補酵素
- 多糖リアーゼ
- カーボンオキシゲンリアーゼ
- リアーゼ
- 抗体、モノクローナル、ヒト化
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 調整錯体
- タキソイド
- シクロデカン
- Diterpenes
- ヘルスケアの経済学と組織
- 経済
- トラスツズマブ
- カルボプラチン
- パクリタキセル
- ヒアルロングルコサミニダーゼ
- 標本処理
- ペルズマブ
- 税金
その他の研究ID番号
- NCI-2022-01540
- U10CA180868 (米国 NIH グラント/契約)
- NCI-2022-01540 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- NRG-GY026 (その他の識別子:CTEP)
- NRG-GY026 (その他の識別子:NRG Oncology)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。